Product List     API & Intermediate     

Inhibitors

Find
130
related chemicals for you
CAS:841205-47-8
Molecular Formula:C19H14F3N3O3
Ostarine; GTx-024; MK-2866; MK-2866(Ostarine); SARM; (2S)-3-(4-Cyanophenoxy)-N-[4-Cyano-3-(Trifluoromethyl)Phenyl]-2-Hydroxy-2-Methylpropanamide; (S)-N-(4-Cyano-3-(Trifluoromethyl)Phenyl)-3-(4-Cyanophenoxy)-2-Hydroxy-2-Methylpropanamide; Ostarine(MK-2866); MK 2866
Brief Introduction
Ostarine (GTx-024, MK-2866) is a selective androgen receptor modulator (SARM) (selective androgen receptor modulator) with Ki of 3.8 nM, which is tissue selective for anabolic organs.
CAS:906093-29-6
Molecular Formula:C44H65Br5N12O2S2
Teneligliptin Hydrobromide Anhydrous; [(2S,4S)-4-[4-(5-Methyl-2-Phenylpyrazol-3-yl)Piperazin-1-yl]Pyrrolidin-2-yl]-(1,3-Thiazolidin-3-yl)Methanone,Pentahydrobromide; Teneligliptin HBr;; Teneligliptin Hydrobromide Anhydrous;; Methanone, ((2S,4S)-4-(4-(3-Methyl-1-Phenyl-1H-Pyrazol-5-yl)-1-Piperazinyl)-2-Pyrrolidinyl)-3-Thiazolidinyl-, Hydrobromide (2:5)
Brief Introduction
Teneligliptin hydrobromide hydrate is a dipeptidyl peptidase-4 (DPP-4) inhibitor, which is suitable for the treatment of type 2 diabetes.
CAS:915087-33-1
Molecular Formula:C21H16F4N4O2S
Mdv 3100; Xtandi; Unii-93T0T9Gknu; [14C]-Enzalutamide; N-Methyl-4-[3-(4-Cyano-3-Trifluoromethylphenyl)-5,5-Dimethyl-4-Oxo-2-Thioxoimidazolidin-1-Yl]-2-Fluorobenzamide; 4-(3-(4-Cyano-3-(Trifluoromethyl)Phenyl)-5,5-Dimethyl-4-Oxo-2-Thioxoimidazolidin-1-Yl)-2-Fluoro-N-Methylbenzamide
Brief Introduction
Enzalutamide is an oral androgen receptor antagonist. At present, it has been approved by clinical research and FDA (food and Drug Administration) for the treatment of metastatic castration tolerant prostate cancer after chemotherapy (i.e. such patients with prostate cancer whose tumor or cancer cells are still growing after chemotherapy), which can prolong the survival time of patients.
CAS:923564-51-6
Molecular Formula:C47H55ClF3N5O6S3
Navitoclax; ABT 263; ABT263; (R)-4-(4-((4'-Chloro-4,4-Dimethyl-3,4,5,6-Tetrahydro-[1,1'-Biphenyl]-2-yl)Methyl)Piperazin-1-yl)-N-((4-((4-Morpholino-1-(Phenylthio)Butan-2-yl)Amino)-3-((Trifluoromethyl)Sulfonyl)Phenyl)Sulfonyl)Benzamide; 4-[4-[[2-(4-Chlorophenyl)-5,5-Dimethyl-1-Cyclohexen-1-yl]Methyl]-1-Piperazinyl]-N-[[4-[[(1R)-3-(4-Morpholinyl)-1-[(Phenylthio)Methyl]Propyl]Amino]-3-[(Trifluoromethyl)Sulfonyl]Phenyl]Sulfonyl]Benzamide; 4-[4-[[2-(4-Chlorophenyl)-5,5-Dimethylcyclohexen-1-yl]Methyl]Piperazin-1-yl]-N-[4-[[(2R)-4-Morpholin-4-yl-1-Phenylsulfanylbutan-2-yl]Amino]-3-(Trifluoromethylsulfonyl)Phenyl]Sulfonylbenzamide; (R)-4-(4-((2-(4-Chlorophenyl)-5,5-Dimethylcyclohex-1-enyl)Methyl)Piperazin-1-yl)-N-(4-(4-Morpholino-1-(Phenylthio)Butan-2-Ylamino)-3-(Trifluoromethylsulfonyl)p; (R)-4-(4-((2-(4-Chlorophenyl)-5,5-Dimethylcyclohex-1-enyl)Methyl)Piperazin-1-yl)-N-(4-(4-Morpholino-1-(Phenylthio)Butan-2-Ylamino)-3-(Trifluoromethylsulfonyl)Phenylsulfonyl)Benzamide; 4-(4-{[2-(4-Chlorophenyl)-5,5-Dimethylcyclohex-1-en-1-yl]Methyl}Piperazin-1-yl)-N-({4-({(1R)-3-Morpholin-4-yl-1-[(Phenylsulfanyl)Methyl]Propyl}Amino)-3-[(Trifluoromethyl)Sulfonyl]Phenyl}Sulfonyl)Benzamide; 4-(4-{[2-(4-Chlorophenyl)-5,5-Dimethylcyclohex-1-En-1-Yl]Methyl}Piperazin-1-Yl)-N-[(4-{[(2r)-4-(Morpholin-4-Yl)-1-(Phenylsulfanyl)Butan-2-Yl]Amino}-3-[(Trifluoromethyl)Sulfonyl]Phenyl)Sulfonyl]Benzamide; Navitoclaxum; C47H55ClF3N5O6S3; 4-(4-((2-(4-Chlorophenyl)-5,5-Dimethylcyclohex-1-EN-1-YL)Methyl)Piperazin-1-YL)-N-((4-(((2R)-4-(Morpholin-4-YL)-1-(Phenylsulfanyl)Butan-2-YL)Amino)-3-((Trifluoromethyl)Sulfonyl)Phenyl)Sulfonyl)Benzamide; ABT-263,Navitoclax; ABT-263 In Bulk; Navitoclax, ABT-263; ABT-263 - Navitoclax; 4-[4-[[2-(4-Chlorophenyl)-5,5-Dimethyl-1-Cyclohexen-1-yl]Methyl]-1-Piperazinyl]-N-[[4-[[(1R)-3-(4-mo; 4-[4-[[2-(4-Chlorophenyl)-5,5-Dimethyl-Cyclohexen-1-yl]Methyl]Piperazin-1-yl]-N-[4-[[(1R)-3-Morpholino-1-(Phenylsulfanylmethyl)Propyl]Amino]-3-(Trifluoromethylsulfonyl)Phenyl]Sulfonyl-Benzamide; 4-[4-[[2-(4-Chlorophenyl)-5,5-Dimet; (R)-4-(4-((4-Chloro-4,4-Dimethyl-3,4,5,6-Tetrahydro-[1,1-Biphenyl]-2-yl)Methyl)Piperazin-1-yl)-N-((4-((4-Morpholino-1-(Phenylthio)Butan-2-yl)Amino)-3-((Trifluoromethyl)Sulfonyl)Phenyl)Sulfonyl)Benzamide; 4-(4-((2-(4-Chlorophenyl)-5,5-Dimethylcyclohex-1-EN-1-YL)Methyl)Piperazin-1-YL)-N-(4-(((2R)-4-(Morpholin-4-YL)-1-(Phenylsulfanyl)Butan-2-YL)Amino)-3-(Trifluoromethanesulfonyl)Benzenesulfonyl)Benzamide; 4-(4-{[2-(4-Chlorophenyl)-5,5-Dimethylcyclohex-1-en-1-yl]Methyl}Piperazin-1-yl)-N-({4-({(1R)-3-(Morpholin-4-yl)-1-[(Phenylsulfanyl)Methyl]Propyl}Amino)-3-[(Trifluoromethyl)Sulfonyl]Phenyl}Sulfonyl)Benzamide; 4-[4-[[2-(4-Chlorophenyl)-5,5-Dimethyl-1-Cyclohexen-1-yl]Methyl]-1-Piperazinyl]-N-[[4-[[(1R)-3-(4-Morpholinyl)-1-[(Phenylthio)Methyl]Propyl]Amino]-3-[(Trifluoromethyl)Sulfonyl]Phenyl]Sulfonyl]Benzamide;ABT 263;Benzamide, 4-(4-((2-(4-Chlorophenyl)-5,5-dime; 4-{4-[(4'-Chloro-4,4-Dimethyl-3,4,5,6-Tetrahydro[Biphenyl]-2-yl)Methyl]Piperazin-1-yl}-N-[(4-{[(2R)-4-(Morpholin-4-yl)-1-(Phenylsulfanyl)Butan-2-yl]Amino}-3-[(Trifluoromethyl)Sulfonyl]Phenyl)Sulfonyl]Benzamide; Benzamide, 4-(4-((2-(4-Chlorophenyl)-5,5-Dimethyl-1-Cyclohexen-1-YL)Methyl)-1- Piperazinyl)-N-((4-(((1R)-3-(4-Morpholinyl)-1-((Phenylthio)Methyl)Propyl)Amino)-3-((Trifluoromethyl)Sulfonyl)Phenyl)Sulfonyl)-; Benzamide, 4-(4-((2-(4-Chlorophenyl)-5,5-Dimethyl-1-Cyclohexen-1-yl)Methyl)-1-Piperazinyl)-N-((4-(((1R)-3-(4-Morpholinyl)-1-((Phenylthio)Methyl)Propyl)Amino)-3-((Trifluoromethyl)Sulfonyl)Phenyl)Sulfonyl)-; N-(4-{4-[2-(4-Chlorophenyl)-5,5-Dimethyl-Cyclohex-1-Enylmethyl]-Piperazin-1-yl}-Benzoyl)-4-((r)-3-Morpholin-4-yl-1-Phenylsulfanylmethyl-Propylamino)-3-Trifluoromethanesulfonyl-Benzenesulfonamide
Brief Introduction
ABT 263 is a new inhibitor of the anti-apoptotic BCL-2 protein; a promising new drug against cancer. It is a potent Bcl-2 family inhibitor.
CAS:17374-26-4
Molecular Formula:C6HBr4N3
4,5,6,7-Tetrabromobenzotriazole; 4,5,6,7-Tetrabromo-2H-Benzotriazole; 4,5,6,7-Tetrabromo-2-Azabenzimidazole 4,5,6,7-Tetrabromobenzotriazole; 4,5,6,7-Tetrabromo-2-Azabenzimidazole,4,5,6,7-Tetrabromobenzotriazole; TBB
Brief Introduction
TBB is one of the most selective protein kinase inhibitors known, and when tested against a panel of 33 serine/threonine and tyrosine protein kinases, only three exhibited moderate inhibition by TBB, with Ki values one to two orders of magnitude higher than that for CK2.
Inquiry ( 
10
 
/ 10
 )
Clear All
Sign In
Please enter your email address correctly
Please enter your password
Forgot Password
OR
Join Free >